Of all the peptides expected to return to legal compounding status under the FDA's anticipated reclassification, BPC-157 may be the most talked about.
It's been studied for more than 30 years. There are nearly 200 published papers on it in the medical literature. And among practitioners who work in regenerative and integrative medicine, it has a reputation that's hard to ignore.
So what is it, exactly? And what does the research actually show?
BPC stands for Body Protection Compound. BPC-157 is a synthetic peptide made up of 15 amino acids — a sequence derived from a protein naturally found in human gastric juice.
It was originally investigated in the 1990s for its potential to protect and heal the gastrointestinal tract. Researchers discovered early on that it appeared to do something unusual: support healing across multiple tissue types, not just the gut. That breadth of activity is part of what has made it one of the most studied peptides in preclinical research.
The vast majority of BPC-157 research has been conducted in animal models. Large-scale human clinical trials are limited, and it's important to be honest about that. What the preclinical data shows, however, is consistent and spans a meaningful range of tissue types.
Areas of research interest include:
A 2021 review published in Frontiers in Pharmacology noted that BPC-157 appears to have consistent activity across tissue types in animal models, with no reported toxicity in the studies conducted. A 2025 systematic review presented at the American College of Gastroenterology described its preclinical profile as showing promise for GI applications — while also noting that human data remains limited and that it should not yet be considered a standard clinical therapy.
That's an accurate summary of where the science stands: genuinely promising preclinical evidence, with the human research still catching up.
In 2023, the FDA moved BPC-157 to its Category 2 restricted list, citing concerns about immunogenicity, impurities, and insufficient safety data for human use. That decision prevented licensed compounding pharmacies from preparing it.
In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that BPC-157 is among the approximately 14 peptides expected to move back to Category 1 status — restoring the ability for licensed compounding pharmacies to prepare it under physician prescription. The formal FDA update is pending publication as of this writing.
Reclassification does not mean FDA approval. BPC-157 has not gone through the large-scale clinical trial process that FDA drug approval requires, and that hasn't changed.
What it does mean is that licensed compounding pharmacies will once again be able to legally prepare BPC-157 for patients with a physician's prescription. That's a meaningful shift from the gray market — where quality control is absent and contamination risks are real — back to pharmaceutical-grade, provider-supervised access.
If you're curious about whether BPC-157 might be appropriate for your health goals, the right starting point is a conversation with a licensed provider who can evaluate your full health picture.
Belle's providers can help you explore your options.
Sources
Belle offers provider-guided compounded medication programs. Peptide compounds are not FDA-approved drugs. Access requires a licensed provider's prescription. Always work with a qualified medical professional before beginning any new therapy.
